Shares of Illumina, the leader in DNA sequencing, have dropped 13% since news leaked last week that the company would be buying Grail, a startup developing a blood test to detect cancer. Obviously, not every investor loves the $8 billion deal.

But in an interview with STAT, the CEOs of the two firms — Illumina’s Francis deSouza and Grail’s Hans Bishop — said it would take time for investors to understand the advantages of combining the two firms. They argue that is particularly true in regard to the potential market for Grail’s two tests: Galleri, which will aim to detect cancer early in apparently healthy people, and a second, unnamed test, which is being designed to test for potential cases of cancer in patients who have symptoms of the disease.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy